The favorable oral pharmacokinetics and robust, sustained functional responses observed with non-catechol D1R agonists in vivo may enable testing of several long-standing therapeutic hypotheses for activating D1R in neurologic and psychiatric illnesses including Parkinson′s disease and schizophrenia. This evidence concerns the gene DRD1 and schizophrenia.